MATCHING-ADJUSTED INDIRECT COMPARISON OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR
a University Hospital, Cologne, Germany
b Eli Lilly and Company, Indianapolis, United States
c TechData Services LLC, United States
d Swedish Cancer Institute, United States
e Churchill Cancer Center, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
f Eli Lilly and Company, Brazil
Lido
859
Vezesque se leu este artigo
382
Total PDF
477
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 18 | 12 | 30 |
| 2025 5 | 61 | 11 | 72 |
| 2025 4 | 43 | 15 | 58 |
| 2025 3 | 44 | 8 | 52 |
| 2025 2 | 35 | 19 | 54 |
| 2025 1 | 27 | 25 | 52 |
| 2024 12 | 17 | 17 | 34 |
| 2024 11 | 28 | 23 | 51 |
| 2024 10 | 15 | 19 | 34 |
| 2024 9 | 29 | 25 | 54 |
| 2024 8 | 27 | 29 | 56 |
| 2024 7 | 16 | 23 | 39 |
| 2024 6 | 24 | 22 | 46 |
| 2024 5 | 17 | 24 | 41 |
| 2024 4 | 17 | 22 | 39 |
| 2024 3 | 19 | 17 | 36 |
| 2024 2 | 11 | 13 | 24 |
| 2024 1 | 6 | 4 | 10 |
| 2023 12 | 7 | 21 | 28 |
| 2023 11 | 9 | 22 | 31 |
| 2023 10 | 7 | 11 | 18 |
Mostrar tudo
